Ignacio Pelaez Fernandez
Research Subjects
Ignacio Pelaez Fernandez has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Alberto de la Cruz
Centro Oncológico de Galicia 14 La Coruña, La Coruña
5 shared publications - Ana Santaballa
Department of Medical Oncology, La Fe University Hospital, IISLaFe, Valencia, Spain
5 shared publications - Antonio Antón-Torres
Hospital Universitario Miguel Servet 15 Zaragoza
5 shared publications - Cesar Augusto Rodriguez
Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
5 shared publications - Cristina Reboredo
University Hospital A Coruña (XXIAC-SERGAS)
5 shared publications - Emilio Alba
Hospital Clínico Universitario Virgen de la Victoria 9 Malaga
5 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Forest plot for the GEICAM/9906 translational study cohort primary endpoint of DRFI, on the FEC vs FEC + P arms for SETER/PR cutpoint “0.75” categories.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Forest plot for the GEICAM/9906 translational study cohort primary endpoint of DRFI, on the FEC vs FEC + P arms for SETER/PR cutpoint “0.75” categories.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Representativeness of Study Participants.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Representativeness of Study Participants.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Patient and baseline characteristics of GEICAM/9906 hormone receptor positive (HR+) breast cancer cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Patient and baseline characteristics of GEICAM/9906 hormone receptor positive (HR+) breast cancer cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Bivariable Cox regression analysis of DRFI between SETER/PR index and EPclin risk score in the GEICAM/9906 translational study cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Bivariable Cox regression analysis of DRFI between SETER/PR index and EPclin risk score in the GEICAM/9906 translational study cohort.
- Open Access
- 26 May 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (17) , 3870-3879
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial
Purpose: To independently validate that low endocrine transcriptional activity measured by SETER/PR index in hormone receptor–positive breast cancer predicts benefit from dose-dense paclitaxel chemotherapy within a second prospective-retrospective biomarker study. Experimental Design: We conducted a blinded, prospective–retrospective biomarker analysis within the GEICAM/9906 trial (NCT00129922), which compared adjuvant FEC followed by weekly paclitaxel (FEC+P) versus six cycles of FEC in lymph node–positive breast cancer. SETER/PR index was measured in all available HR+/HER2– tumor RNA samples using a pre-specified cutpoint (<0.75). The primary endpoint was distant recurrence–free interval (DRFI); secondary endpoints were overall survival (OS) and breast cancer–specific survival (BCSS). Results: Of 647 HR+/HER2– tumors, 567 (87.6%) passed assay quality control (279 FEC+P; 288 FEC). Low SETER/PR index was identified in 92 tumors (16.2%). There was a significant interaction between SETER/PR status and treatment on DRFI (p=0.046). Among patients with low SETER/PR index, FEC+P significantly improved DRFI (HR 0.46; 95% CI, 0.22–0.95; p=0.035), with similar results after adjustment (HR 0.48; 95% CI, 0.24–1.00; p=0.049). No treatment benefit was observed for SETER/PR ≥0.75 (HR 1.02; 95% CI, 0.70–1.47; p=0.931). Differences in OS and BCSS did not reach significance. Conclusions: Low endocrine transcriptional activity predicts benefit from adding weekly paclitaxel to anthracycline-based adjuvant chemotherapy in HR+/HER2– breast cancer. These findings independently validate SETER/PR index as a predictive biomarker for paclitaxel-based chemotherapy and support its potential role in guiding regimen selection.
- 26 May 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (17) , 3870-3879
Open AccessSensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial
Purpose: To independently validate that low endocrine transcriptional activity measured by SETER/PR index in hormone receptor–positive breast cancer predicts benefit from dose-dense paclitaxel chemotherapy within a second prospective-retrospective biomarker study. Experimental Design: We conducted a blinded, prospective–retrospective biomarker analysis within the GEICAM/9906 trial (NCT00129922), which compared adjuvant FEC followed by weekly paclitaxel (FEC+P) versus six cycles of FEC in lymph node–positive breast cancer. SETER/PR index was measured in all available HR+/HER2– tumor RNA samples using a pre-specified cutpoint (<0.75). The primary endpoint was distant recurrence–free interval (DRFI); secondary endpoints were overall survival (OS) and breast cancer–specific survival (BCSS). Results: Of 647 HR+/HER2– tumors, 567 (87.6%) passed assay quality control (279 FEC+P; 288 FEC). Low SETER/PR index was identified in 92 tumors (16.2%). There was a significant interaction between SETER/PR status and treatment on DRFI (p=0.046). Among patients with low SETER/PR index, FEC+P significantly improved DRFI (HR 0.46; 95% CI, 0.22–0.95; p=0.035), with similar results after adjustment (HR 0.48; 95% CI, 0.24–1.00; p=0.049). No treatment benefit was observed for SETER/PR ≥0.75 (HR 1.02; 95% CI, 0.70–1.47; p=0.931). Differences in OS and BCSS did not reach significance. Conclusions: Low endocrine transcriptional activity predicts benefit from adding weekly paclitaxel to anthracycline-based adjuvant chemotherapy in HR+/HER2– breast cancer. These findings independently validate SETER/PR index as a predictive biomarker for paclitaxel-based chemotherapy and support its potential role in guiding regimen selection.